DZD 6008
Alternative Names: DZD-6008Latest Information Update: 10 Sep 2024
At a glance
- Originator Dizal Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Epidermal growth factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 28 Aug 2024 Dizal Pharmaceutical plans the phase I TIAN-SHAN2 trial in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second line therapy or greater) in China (PO) (CTR20241790)
- 28 Aug 2024 Preclinical trials in Solid tumours in China (PO) prior to August 2024 (Dizal Pharmaceutical pipeline, August 2024)